From 2018 to 2022, IPATH initiated phage hunts for 265 patients, but 25% couldn’t proceed due to lack of phages. IPATH has now partnered with Korean phage company MicrobiotiX; IPATH will screen and send sample isolates to MicrobiotiX, who will screen and send phages back to IPATH.